FDA Advisory Committee recommends Gattex (NPS Pharma) for Short Bowel Syndrome

The FDA Gastrointestinal Drugs Advisory Committee voted unanimously to recommend approval of Gattex (teduglutide) from NPS Pharma. It voted 12-0 that the drug delivered meaningful benefits as a treatment for Short Bowel Syndrome (SBS) and that the benefits of the drug outweigh its potential risks.The drug was approved in September 2012 in the EU for Nycomed/Takeda as Revestive